TL;DR
Six senior executives dispose of shares worth millions as the genetic testing company trades near elevated valuations.
July 23, 2025
Multiple Executives Participate in Coordinated Sales
Natera Inc. (NASDAQ: NTRA) experienced significant insider selling activity throughout July 2025, with six senior executives disposing of shares worth several million dollars collectively.
The sales occurred as the genetic testing company trades near elevated valuations following strong financial performance.
Executive Transaction Breakdown
Daniel Rabinowitz
Chief Legal Officer Daniel Rabinowitz led the selling activity, disposing of 20,372 shares between June 18 and July 21 for total proceeds of approximately $3.4 million.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan at prices ranging from $139.29 to $171.4973 per share.
Steven Leonard Chapman
CEO Steven Leonard Chapman sold 1,622 shares on July 21 at $139.29 per share, generating $225,928 in proceeds.
The transaction followed Chapman’s acquisition of 3,386 shares through restricted stock unit vesting on July 20.
Brophy Michael Burkes
Chief Financial Officer Brophy Michael Burkes executed a smaller transaction, selling 602 shares on July 21 at the same $139.29 price point for total proceeds of $83,852.
The sale reduced Brophy’s holdings to 71,414 shares following the exercise of options for 1,522 shares on July 20.
Solomon Moshkevich
President of Clinical Diagnostics Solomon Moshkevich completed two separate transactions totaling $299,179.
The executive sold 1,649 shares on May 27 at $156.8505 per share, followed by a July 21 sale of 291 shares at $139.29 per share.
Sheena Jonathan
Co-Founder and Director Sheena Jonathan rounded out the July insider activity with a modest sale of 93 shares on July 21 at $139.29, totaling $12,953.
The transaction was executed to cover tax obligations related to restricted stock unit vesting.
John Fesko
President and Chief Business Officer John Fesko also participated in significant selling activity earlier in 2025, with multiple transactions spanning January through May.
His most recent sale occurred on May 27, 2025, involving 1,438 shares as part of ongoing equity compensation management.
Market Context and Valuation
The insider sales coincide with Natera’s strong financial momentum. The company reported first-quarter 2025 earnings that exceeded analyst expectations, with revenue reaching $522 million and representing a 37% year-over-year increase.
The genetic testing specialist has delivered robust revenue growth of 51.5% over the past twelve months.
Natera currently maintains a market capitalization of approximately $19.17 billion. Analyst sentiment remains positive, with multiple firms maintaining outperform ratings:
- RBC Capital Markets holds a $251 price target
- TD Cowen recently raised its target to $200 following strong sales performance
Strategic Developments
The insider activity occurs amid expanding Medicare coverage for Natera’s Signatera MRD assay, now covering a broader range of cancers including colorectal, breast, and lung.
Clinical volumes for the Signatera product increased 52% year-over-year to approximately 17,000 in the first quarter.
Most transactions were conducted under pre-established Rule 10b5-1 trading plans or to satisfy tax withholding obligations related to equity compensation, suggesting routine portfolio management rather than concerns about company fundamentals.